Comparing two treatments for locally advanced pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness and safety of NALIRINOX combined with PD-1 sequential radiotherapy versus AG combined with PD-1 sequential radiotherapy as first-line treatment for patients with locally advanced pancreatic cancer. Participants will receive either treatment regimen to determine which is more effective in managing their condition. The study aims to provide insights into the best therapeutic approach for this challenging cancer type.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologically or cytologically confirmed pancreatic cancer;
2. ECOG performance no more than 2;
3. Radiographically assessed as locally advanced pancreatic cancer according to NCCN guidelines;
4. No previous anti-tumor therapy；
5. Able and willing to provide a written informed consent;

Exclusion Criteria:

* 1\. Prior anti-tumor therapy of any kind; 2. Severe infection (\>NCI CTC grade 2); 3.Patients with autoimmune disease or immune deficiency who are treated with immunosuppressive drugs; 4.Patients with bleeding tendency; 5. Pregnant or lactating women.

Where it's running

• The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
  Nanjing, Jiangsu, China Recruiting
• FirstNanjingMU
  Nanjing, Jiangsu, China Not yet recruiting

Study contacts

• Principal investigator: Juan Du — The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
• Study coordinator: Juan Du, M.D. Ph.D
• Email: dujunglyy@163.com
• Phone: +86-025-83106666

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Chemotherapy followed by ablative SBRT for locally advanced inoperable pancreatic cancer

  This trial will try chemotherapy followed by high-dose focused radiation (SBRT) as the first treatment for adults with locally advanced, inoperable pancreatic cancer.

  Recruiting Institute of Oncology Ljubljana · Ljubljana · NCT07407231

• Chemotherapy With IMD10 (Focused Ultrasound) for Borderline Resectable or Locally Advanced Pancreatic Cancer

  This trial tests whether adding IMD10 focused ultrasound to a standard chemotherapy regimen helps people with borderline resectable or locally advanced pancreatic cancer see better survival.

  Recruiting IMGT Co., Ltd. · Boston, Massachusetts and 4 other locations · NCT07325214

• Personalized management for borderline resectable and locally advanced pancreatic cancer

  This study is testing if giving chemotherapy first can help people with borderline resectable and locally advanced pancreatic cancer have surgery and improve their chances of survival.

  Recruiting Oslo University Hospital · Bergen, Norway and 4 other locations · NCT06944587

• Combination treatment for advanced pancreatic cancer

  This study is testing a new combination treatment for advanced pancreatic cancer to see if it helps patients who haven't had treatment before.

  Recruiting Phase 1/2 Fujian Provincial Hospital · Fuzhou, Fujian and 3 other locations · NCT06761027

• Alpha DaRT for Locally Advanced Pancreatic Cancer test

  This trial tests inserting Alpha DaRT sources into a locally advanced pancreatic tumor to see if it can become resectable.

  Recruiting Alpha Tau Medical LTD. · Bordeaux and 11 other locations · NCT06755359

• Assessing the effects of radiotherapy on tumors in cervical and pancreatic cancer

  This study is testing how radiotherapy affects tumors in patients with locally advanced cervical and pancreatic cancer by collecting samples and using special imaging before, during, and after treatment.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT05975593

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.